Astrazeneca Pharma India Ltd logo

Astrazeneca Pharma India Ltd

ASTRAZEN NSE

AstraZeneca Pharma India Ltd is engaged in the business of manufacture, distribution and marketing of pharmaceutical products.[1]

AI Verdict: HOLD Confidence: 5%

Astrazeneca Pharma India delivers strong revenue growth at 33% TTM and consistent ROE of 23%, but trades at an extremely expensive PE of 113.5x and 24.4x book value, leaving little margin of safety. The stock has declined 5% over the past year despite robust fundamentals, suggesting the market is already pricing in future growth.

Key Fundamentals

SmallcapPharmaceuticalsHealthcare
Market Cap
₹21,208 Cr
Volatility
Moderate
P/E Ratio
111.87
EBITDA
₹295 Cr
Return on Equity
22.69%
Debt to Equity
0.03
Book Value
₹349.12
EPS
₹52.4
52W High
₹9,849.5
52W Low
₹7,551.5

Technical Indicators

Key Insights

Strengths

2
  • Company is expected to give good quarter
  • Company has been maintaining a healthy dividend payout of 51.4%

Weaknesses

1
  • Stock is trading at 24.2 times its book value

Growth Rate

Revenue Growth
32.07% ↗
Net Income Growth
-28.36% ↘
Cash Flow Change
134.52% ↗
ROE
-33.80% ↘
ROCE
-36.77% ↘
EBITDA Margin (Avg.)
1.76% ↘

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 3d ago
HOLD
Risk high

Astrazeneca Pharma India delivers strong revenue growth at 33% TTM and consistent ROE of 23%, but trades at an extremely expensive PE of 113.5x and 24.4x book value, leaving little margin of safety. The stock has declined 5% over the past year despite robust fundamentals, suggesting the market is already pricing in future growth.

Bull Case 8
  • Exceptional TTM sales growth of 33% indicates strong demand momentum and successful product launches
  • Consistent ROE of 23% over 1, 3, and 5 years demonstrates high-quality capital allocation and asset-light business model
  • 10-year compounded profit growth of 43% CAGR reflects sustained long-term earnings power
  • 3-year stock CAGR of 32% shows the market has rewarded the company's execution over medium term
  • Healthy dividend payout ratio of 51.4% with 0.38% yield signals shareholder-friendly management despite being a growth company
  • 5-year compounded sales growth of 23% demonstrates consistent top-line expansion well above industry average
  • Company is expected to deliver a good upcoming quarter, suggesting near-term earnings catalyst
  • 10-year stock CAGR of 23% shows long-term wealth creation track record backed by MNC parentage
Bear Case 8
  • PE ratio of 113.5x is extremely elevated even for a pharma MNC, pricing in many years of perfect execution
  • Price-to-book of 24.4x is excessively rich, leaving significant downside risk if growth disappoints
  • TTM profit growth of only 9% versus sales growth of 33% indicates margin compression or rising costs
  • Stock has delivered negative 5% return over the past 1 year despite strong operational performance, signaling valuation fatigue
  • Zero analyst coverage means no institutional consensus or price targets to anchor valuation expectations
  • Dividend yield of just 0.38% provides negligible downside cushion at current elevated prices
  • 5-year stock CAGR of 18% lags the 5-year profit CAGR of 16% only marginally, suggesting limited re-rating potential from here
  • 3-year profit CAGR of 15% significantly trails 3-year sales CAGR of 31%, indicating operating leverage is not translating to bottom line

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 14h ago
Headwinds 4
  • Q4 profit drops 23%, margins compress May 27

    Net profit fell 23% YoY to ₹44.88 crore in Q4FY26. EBITDA margin contracted sharply from 17.9% to 10.5% as total expenses rose 27.36% to ₹525.34 crore.

  • GST order of ₹9.24 crore Jun 4

    Received adverse GST order for FY 2018-19 involving claims of ₹9.24 crore from Deputy Commissioner of State Tax (Appeal). Company plans to challenge before GST Appellate Tribunal.

  • Multiple senior executives resign Jun 1

    Four senior officials departed in quick succession — Ayush Kumar Agarwal, Shikha Mirchandani Chatrath (Jun/Aug 2026), Aditi Mehta (Jun 12), and Srikanth B.S. (Jun 15) — raising leadership continuity concerns.

  • Factory license surrendered Jun 3

    Surrendered factory license to the Department of Factories, Boilers, Industrial Safety and Health on June 3, 2026, indicating shift away from domestic manufacturing.

Positives 4
  • FY26 revenue up 33%, profit up 62% May 26

    Full-year revenue rose 32.58% to ₹2,275.58 crore and net profit surged 62% to ₹187.52 crore in FY26, with 11 new regulatory approvals secured during the year.

  • Trastuzumab Deruxtecan approval received Jun 11

    Received regulatory approval to import and sell Trastuzumab Deruxtecan in India, a significant oncology portfolio addition enabling commercial availability.

  • ₹36/share dividend (1800% of face value) May 26

    Board recommended final dividend of ₹36 per share for FY26, translating to 1800% of face value of ₹2, signaling confidence in financial position.

  • Q4 revenue grows 20% YoY May 27

    Revenue from operations rose 20.42% to ₹578.61 crore in Q4FY26 from ₹480.48 crore a year ago, driven by Oncology and Biopharmaceuticals momentum.

Neutral 4
  • New Director Corporate Affairs appointed Jun 16

    Praveen K Mittal appointed as Director - Corporate Affairs effective July 6, 2026.

  • Trading window closed for Q1 results Jun 15

    Trading window closed from June 16, 2026, until 48 hours after Q1FY27 results declaration per insider trading regulations.

  • No encumbrance on promoter shares Jun 9

    Promoter AstraZeneca Pharmaceuticals AB confirmed zero encumbrance on shares for FY26 under SEBI Takeover Regulations.

  • Stock consolidating near key support May 27

    Stock trading in broad consolidation on weekly chart with 50-week EMA support near ₹8,100 and resistance at ₹8,500-₹8,600. Breakout could target ₹9,200-₹10,000.

TL;DR: AstraZeneca Pharma India delivered strong FY26 annual growth (revenue +33%, profit +62%) and secured a key oncology drug approval, but Q4 margin compression (EBITDA margin down to 10.5% from 17.9%) and a wave of senior departures are near-term concerns. The generous ₹36/share dividend and new product approvals signal parent confidence. The trend remains constructive on an annual basis, though rising expenses and leadership churn need monitoring in coming quarters.

Quarterly Results

  Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales
285
295
311
306
383
388
408
440
480
526
559
612
579
Expenses
225
228
258
291
334
349
355
363
394
445
484
567
518
Operating Profit
60
67
53
15
49
38
53
77
86
81
75
45
61
OPM %
21%
23%
17%
5%
13%
10%
13%
17%
18%
15%
13%
7%
11%
Other Income
-32
8
25
10
9
-49
8
-26
10
11
1
7
5
Interest
0
0
0
1
0
0
0
0
1
1
1
1
2
Depreciation
4
4
4
4
4
4
9
9
18
17
3
4
6
PBT
23
71
73
20
54
-15
51
42
78
75
73
47
58
Tax %
26%
25%
29%
23%
27%
-22%
25%
27%
26%
25%
26%
30%
23%
Net Profit
17
54
52
16
39
-12
38
31
58
56
54
33
45
EPS in Rs
6.91
21.54
20.95
6.32
15.79
-4.72
15.37
12.34
23.3
22.33
21.69
13.04
17.95
Figures in ₹ Crores

Profit & Loss

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales
517
564
544
571
728
832
814
806
1,003
1,296
1,716
2,276
Expenses
528
547
506
525
657
711
678
719
838
1,111
1,462
2,014
Operating Profit
-11
16
37
46
71
121
135
86
165
184
254
262
OPM %
-2%
3%
7%
8%
10%
15%
17%
11%
16%
14%
15%
12%
Other Income
6
7
14
12
16
13
13
15
-14
51
-56
23
Interest
0
0
0
0
0
1
1
1
1
1
1
4
Depreciation
15
17
16
15
15
19
20
17
16
15
40
29
PBT
-21
6
36
44
73
114
127
83
134
220
156
252
Tax %
0%
9%
44%
41%
25%
37%
27%
26%
26%
26%
26%
26%
Net Profit
-21
5
20
26
54
72
93
62
99
162
116
188
EPS in Rs
-8.34
2.1
8.02
10.36
21.78
28.88
37.32
24.64
39.72
64.6
46.3
75.01
Div. Payout %
0%
0%
0%
0%
0%
3%
5%
41%
40%
37%
69%
48%
Figures in ₹ Crores

Balance Sheet

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
5
5
5
5
5
5
5
5
5
5
5
5
Reserves
146
151
218
242
296
359
451
506
584
707
765
868
Borrowings
0
0
0
0
0
12
12
9
7
5
36
111
Other Liabilities
261
247
193
214
261
330
306
337
389
362
712
1,006
Total Liabilities
412
403
415
461
562
706
775
857
985
1,078
1,518
1,989
Fixed Assets
101
97
87
75
75
72
81
74
69
67
64
117
CWIP
12
6
5
4
7
24
4
2
1
0
0
0
Investments
0
0
0
0
0
0
0
0
0
0
0
0
Other Assets
298
299
324
382
480
611
690
780
915
1,011
1,454
1,872
Total Assets
412
403
415
461
562
706
775
857
985
1,078
1,518
1,989
Figures in ₹ Crores

Cash Flow

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
-46
57
38
9
55
87
105
101
58
28
65
-15
Investing
-19
-4
0
-9
4
-171
173
5
18
22
31
19
Financing
0
-1
0
0
0
-6
-9
-9
-24
-44
-66
-92
Net Cash Flow
-64
53
38
-1
59
-90
269
96
52
5
31
-88
Free Cash Flow
-69
48
33
3
37
74
99
94
53
18
64
-18
CFO/OP
393
365
133
28
126
100
101
146
60
46
51
26
Figures in ₹ Crores

Ratios

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
30
54
29
35
40
37
38
39
39
43
39
34
Inventory Days
157
141
121
229
186
197
198
164
193
140
208
272
Days Payable
203
174
184
257
266
251
221
223
231
121
173
207
Cash Conversion Cycle
-16
21
-34
7
-39
-17
15
-20
1
62
74
99
Working Capital Days
-15
-28
-36
-8
-14
-16
-17
-34
-18
20
22
50
ROCE %
-13%
4%
15%
19%
27%
34%
30%
16%
31%
31%
33%
29%

Shareholding Pattern

As of Mar 2026
Promoters 75.00%
Public 13.88%
DIIs 5.80%
FIIs 2.78%
Others 2.55%
Total 100.01%
  Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters
75.00%
75.00%
75.00%
75.00%
75.00%
75.00%
75.00%
75.00%
75.00%
75.00%
75.00%
75.00%
75.00%
75.00%
75.00%
75.00%
75.00%
75.00%
75.00%
75.00%
75.00%
FIIs
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
2.69%
0.00%
2.74%
2.79%
2.90%
2.93%
2.89%
3.03%
2.74%
2.71%
2.78%
DIIs
0.83%
0.94%
0.96%
1.00%
1.02%
1.10%
1.12%
1.44%
1.42%
1.93%
2.43%
2.75%
3.78%
5.01%
5.10%
5.22%
4.65%
4.56%
5.26%
5.56%
5.80%
Government
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Public
19.53%
19.72%
19.69%
19.44%
19.06%
18.62%
18.54%
18.56%
18.46%
18.12%
17.44%
17.09%
16.33%
15.00%
14.77%
14.62%
15.16%
15.18%
14.39%
14.14%
13.88%
Others
4.64%
4.34%
4.34%
4.57%
4.92%
5.28%
5.34%
5.01%
5.12%
4.95%
2.44%
5.15%
2.15%
2.20%
2.23%
2.24%
2.31%
2.23%
2.61%
2.59%
2.55%
No. of Shareholders
0
63,753
68,077
66,444
62,183
57,760
53,980
49,085
42,146
38,946
32,380
29,032
29,418
27,169
27,615
27,322
32,466
34,378
32,914
31,551
29,007

Documents

Frequently Asked Questions about Astrazeneca Pharma India Ltd

What does Astrazeneca Pharma India Ltd do?
AstraZeneca Pharma India Ltd is engaged in the business of manufacture, distribution and marketing of pharmaceutical products.[1]
Where is Astrazeneca Pharma India Ltd (ASTRAZEN) listed?
Astrazeneca Pharma India Ltd is listed on the Indian stock exchanges. It is listed on NSE: ASTRAZEN and BSE: 506820. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Astrazeneca Pharma India Ltd belong to?
Astrazeneca Pharma India Ltd operates in the Healthcare sector within the Pharmaceuticals & Biotechnology industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Astrazeneca Pharma India Ltd?
Astrazeneca Pharma India Ltd has a market capitalisation of approximately ₹21207.50 Cr. Based on this, it is classified as a Large Cap stock.
What is the PE ratio of Astrazeneca Pharma India Ltd?
The Price-to-Earnings (PE) ratio of Astrazeneca Pharma India Ltd is 111.87. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Astrazeneca Pharma India Ltd?
Over the past 52 weeks, Astrazeneca Pharma India Ltd has traded between a low of ₹7,551.5 and a high of ₹9,849.5. This range helps investors understand the stock's price volatility and recent trading levels.
Does Astrazeneca Pharma India Ltd pay dividends?
Yes, Astrazeneca Pharma India Ltd has a dividend yield of 0.38%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Astrazeneca Pharma India Ltd?
Astrazeneca Pharma India Ltd has a Return on Equity (ROE) of 22.69%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Astrazeneca Pharma India Ltd on Tapetide?
On Tapetide, you can view Astrazeneca Pharma India Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

AstraZeneca Pharma India Ltd is engaged in the business of manufacture, distribution and marketing of pharmaceutical products.[1]

Website astrazenecaindia.com
CEO Ms. Bhavana Agrawal
Employees 600
Listed 2001-05-04
Face Value ₹ 2
Issued Size 2,50,00,000

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List